Sangamo BioSciences Provides Update On Phase 1 Safety Trial Of SB-728-T For HIV/AIDS

November 20, 2009 by admin 

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo’s zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.

Source: Sangamo BioSciences Provides Update On Phase 1 Safety Trial Of SB-728-T For HIV/AIDS

Comments

Comments are closed.